{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T18:00:05Z","timestamp":1787162405070,"version":"build-2736575974"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2018,7,16]],"date-time":"2018-07-16T00:00:00Z","timestamp":1531699200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Genet"],"published-print":{"date-parts":[[2018,8]]},"DOI":"10.1038\/s41588-018-0168-y","type":"journal-article","created":{"date-parts":[[2018,7,13]],"date-time":"2018-07-13T12:29:48Z","timestamp":1531484988000},"page":"1081-1085","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":39,"title":["Common variation near IRF6 is associated with IFN-\u03b2-induced liver injury in multiple sclerosis"],"prefix":"10.1038","volume":"50","author":[{"given":"Kaarina","family":"Kowalec","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2415-7339","authenticated-orcid":false,"given":"Galen E. B.","family":"Wright","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3348-5855","authenticated-orcid":false,"given":"Britt I.","family":"Dr\u00f6gem\u00f6ller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Folefac","family":"Aminkeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amit P.","family":"Bhavsar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elaine","family":"Kingwell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric M.","family":"Yoshida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony","family":"Traboulsee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruth Ann","family":"Marrie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcelo","family":"Kremenchutzky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Trudy L.","family":"Campbell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre","family":"Duquette","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naga","family":"Chalasani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6368-2622","authenticated-orcid":false,"given":"Mia","family":"Wadelius","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P\u00e4r","family":"Hallberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zongqi","family":"Xia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8057-2505","authenticated-orcid":false,"given":"Philip L.","family":"De Jager","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua C.","family":"Denny","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary F.","family":"Davis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Colin J. D.","family":"Ross","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5804-2535","authenticated-orcid":false,"given":"Helen","family":"Tremlett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruce C.","family":"Carleton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,7,16]]},"reference":[{"key":"168_CR1","doi-asserted-by":"publisher","first-page":"815","DOI":"10.2165\/00002018-200326110-00006","volume":"26","author":"GS Francis","year":"2003","unstructured":"Francis, G. S. et al. Hepatic reactions during treatment of multiple sclerosis with interferon-\u03b2-1a: incidence and clinical significance. Drug Saf. 26, 815\u2013827 (2003).","journal-title":"Drug Saf."},{"key":"168_CR2","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1177\/1352458510388823","volume":"17","author":"S Chan","year":"2011","unstructured":"Chan, S., Kingwell, E., Oger, J., Yoshida, E. & Tremlett, H. High-dose frequency beta-interferons increase the risk of liver test abnormalities in multiple sclerosis: a longitudinal study. Mult. Scler. 17, 361\u2013367 (2011).","journal-title":"Mult. Scler."},{"key":"168_CR3","doi-asserted-by":"publisher","first-page":"1305","DOI":"10.1517\/14740338.2014.947958","volume":"13","author":"K Kowalec","year":"2014","unstructured":"Kowalec, K. et al. Characteristics associated with drug-induced liver injury from interferon beta in multiple sclerosis patients. Expert Opin. Drug Saf. 13, 1305\u20131317 (2014).","journal-title":"Expert Opin. Drug Saf."},{"key":"168_CR4","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1038\/ng.379","volume":"41","author":"AK Daly","year":"2009","unstructured":"Daly, A. K. et al. HLA-B*5701 genotype is a major determinant of drug-induced liver injury due to flucloxacillin. Nat. Genet. 41, 816\u2013819 (2009).","journal-title":"Nat. Genet."},{"key":"168_CR5","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1038\/ng.632","volume":"42","author":"JB Singer","year":"2010","unstructured":"Singer, J. B. et al. A genome-wide study identifies HLA alleles associated with lumiracoxib-related liver injury. Nat. Genet. 42, 711\u2013714 (2010).","journal-title":"Nat. Genet."},{"key":"168_CR6","doi-asserted-by":"publisher","first-page":"947","DOI":"10.7326\/0003-4819-137-12-200212170-00007","volume":"137","author":"G Ostapowicz","year":"2002","unstructured":"Ostapowicz, G. et al. Results of a prospective study of acute liver failure at 17 tertiary care centers in the United States. Ann. Intern. Med. 137, 947\u2013954 (2002).","journal-title":"Ann. Intern. Med."},{"key":"168_CR7","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1056\/NEJMra052270","volume":"354","author":"VJ Navarro","year":"2006","unstructured":"Navarro, V. J. & Senior, J. R. Drug-related hepatotoxicity. N. Engl. J. Med. 354, 731\u2013739 (2006).","journal-title":"N. Engl. J. Med."},{"key":"168_CR8","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1200\/JCO.2010.31.3197","volume":"29","author":"CF Spraggs","year":"2011","unstructured":"Spraggs, C. F. et al. HLA-DQA1*02:01 is a major risk factor for lapatinib-induced hepatotoxicity in women with advanced breast cancer. J. Clin. Oncol. 29, 667\u2013673 (2011).","journal-title":"J. Clin. Oncol."},{"key":"168_CR9","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1038\/clpt.2011.58","volume":"89","author":"GP Aithal","year":"2011","unstructured":"Aithal, G. P. et al. Case definition and phenotype standardization in drug-induced liver injury. Clin. Pharmacol. Ther. 89, 806\u2013815 (2011).","journal-title":"Clin. Pharmacol. Ther."},{"key":"168_CR10","first-page":"23","volume":"9","author":"MR Nelson","year":"2009","unstructured":"Nelson, M. R. et al. Genome-wide approaches to identify pharmacogenetic contributions to adverse drug reactions. Pharm. J. 9, 23\u201333 (2009).","journal-title":"Pharm. J."},{"key":"168_CR11","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1126\/science.1262110","volume":"348","author":"GTEx Consortium.","year":"2015","unstructured":"GTEx Consortium. The Genotype-Tissue Expression (GTEx) pilot analysis: multitissue gene regulation in humans. Science 348, 648\u2013660 (2015).","journal-title":"Science"},{"key":"168_CR12","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1038\/nri1900","volume":"6","author":"K Honda","year":"2006","unstructured":"Honda, K. & Taniguchi, T. IRFs: master regulators of signalling by Toll-like receptors and cytosolic pattern-recognition receptors. Nat. Rev. Immunol. 6, 644\u2013658 (2006).","journal-title":"Nat. Rev. Immunol."},{"key":"168_CR13","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/j.jhep.2014.08.022","volume":"62","author":"PX Wang","year":"2015","unstructured":"Wang, P. X. et al. Interferon regulatory factor 9 is a key mediator of hepatic ischemia\/reperfusion injury. J. Hepatol. 62, 111\u2013120 (2015).","journal-title":"J. Hepatol."},{"key":"168_CR14","doi-asserted-by":"publisher","first-page":"894","DOI":"10.1177\/1352458514555786","volume":"21","author":"SE Baranzini","year":"2015","unstructured":"Baranzini, S. E. et al. Prognostic biomarkers of IFN\u03b2 therapy in multiple sclerosis patients. Mult. Scler. 21, 894\u2013904 (2015).","journal-title":"Mult. Scler."},{"key":"168_CR15","first-page":"438","volume":"156","author":"M Mosedale","year":"2017","unstructured":"Mosedale, M. et al. Candidate risk factors and mechanisms for tolvaptan-induced liver injury are identified using a Collaborative Cross approach. Toxicol. Sci. 156, 438\u2013454 (2017).","journal-title":"Toxicol. Sci."},{"key":"168_CR16","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1007\/s10571-015-0217-3","volume":"36","author":"Y Lin","year":"2016","unstructured":"Lin, Y. et al. Upregulation of interferon regulatory factor 6 promotes neuronal apoptosis after traumatic brain injury in adult rats. Cell Mol. Neurobiol. 36, 27\u201336 (2016).","journal-title":"Cell Mol. Neurobiol."},{"key":"168_CR17","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/S1665-2681(19)32043-5","volume":"5","author":"V Byrnes","year":"2006","unstructured":"Byrnes, V., Afdhal, N., Challies, T. & Greenstein, P. E. Drug induced liver injury secondary to interferon-beta (IFN-\u03b2) in multiple sclerosis. Ann. Hepatol. 5, 56\u201359 (2006).","journal-title":"Ann. Hepatol."},{"key":"168_CR18","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1002\/hep.22370","volume":"48","author":"MI Lucena","year":"2008","unstructured":"Lucena, M. I. et al. Glutathione S-transferase m1 and t1 null genotypes increase susceptibility to idiosyncratic drug-induced liver injury. Hepatology 48, 588\u2013596 (2008).","journal-title":"Hepatology"},{"key":"168_CR19","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1053\/j.gastro.2006.11.023","volume":"132","author":"AK Daly","year":"2007","unstructured":"Daly, A. K. et al. Genetic susceptibility to diclofenac-induced hepatotoxicity: contribution of UGT2B7, CYP2C8, and ABCC2 genotypes. Gastroenterology 132, 272\u2013281 (2007).","journal-title":"Gastroenterology"},{"key":"168_CR20","doi-asserted-by":"publisher","first-page":"491","DOI":"10.2165\/11591110-000000000-00000","volume":"25","author":"BC Kieseier","year":"2011","unstructured":"Kieseier, B. C. The mechanism of action of interferon-\u03b2 in relapsing multiple sclerosis. CNS Drugs 25, 491\u2013502 (2011).","journal-title":"CNS Drugs"},{"key":"168_CR21","doi-asserted-by":"publisher","first-page":"1126","DOI":"10.1056\/NEJMoa1009717","volume":"364","author":"P Chen","year":"2011","unstructured":"Chen, P. et al. Carbamazepine-induced toxic effects and HLA-B*1502 screening in Taiwan. N. Engl. J. Med. 364, 1126\u20131133 (2011).","journal-title":"N. Engl. J. Med."},{"key":"168_CR22","doi-asserted-by":"publisher","first-page":"A387","DOI":"10.1016\/j.autrev.2009.11.010","volume":"9","author":"R Milo","year":"2010","unstructured":"Milo, R. & Kahana, E. Multiple sclerosis: geoepidemiology, genetics and the environment. Autoimmun. Rev. 9, A387\u2013A394 (2010).","journal-title":"Autoimmun. Rev."},{"key":"168_CR23","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1002\/ana.410130302","volume":"13","author":"CM Poser","year":"1983","unstructured":"Poser, C. M. et al. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann. Neurol. 13, 227\u2013231 (1983).","journal-title":"Ann. Neurol."},{"key":"168_CR24","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1002\/ana.22366","volume":"69","author":"CH Polman","year":"2011","unstructured":"Polman, C. H. et al. Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann. Neurol. 69, 292\u2013302 (2011).","journal-title":"Ann. Neurol."},{"key":"168_CR25","doi-asserted-by":"publisher","first-page":"1766","DOI":"10.1007\/s10620-012-2553-1","volume":"58","author":"RJ Fontana","year":"2013","unstructured":"Fontana, R. J. et al. Presentation and outcomes with clinically apparent interferon beta hepatotoxicity. Dig. Dis. Sci. 58, 1766\u20131775 (2013).","journal-title":"Dig. Dis. Sci."},{"key":"168_CR26","doi-asserted-by":"publisher","first-page":"55","DOI":"10.2165\/00002018-200932010-00005","volume":"32","author":"RJ Fontana","year":"2009","unstructured":"Fontana, R. J. et al. Drug-Induced Liver Injury Network (DILIN) prospective study: rationale, design and conduct. Drug Saf. 32, 55\u201368 (2009).","journal-title":"Drug Saf."},{"key":"168_CR27","unstructured":"De Jager, P. L. et al. Meta-analysis of genome scans and replication identify CD6, IRF8 and TNFRSF1A as new multiple sclerosis susceptibility loci. Nat. Genet. 41, 776\u2013782 (2009)."},{"key":"168_CR28","doi-asserted-by":"publisher","DOI":"10.1186\/s13742-015-0047-8","volume":"4","author":"CC Chang","year":"2015","unstructured":"Chang, C. C. et al. Second-generation PLINK: rising to the challenge of larger and richer datasets. Gigascience 4, 7 (2015).","journal-title":"Gigascience"},{"key":"168_CR29","doi-asserted-by":"publisher","DOI":"10.1186\/1756-0500-7-901","volume":"7","author":"P Deelen","year":"2014","unstructured":"Deelen, P. et al. Genotype harmonizer: automatic strand alignment and format conversion for genotype data integration. BMC Res. Notes 7, 901 (2014).","journal-title":"BMC Res. Notes"},{"key":"168_CR30","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1038\/nature15393","volume":"526","author":"1000 Genomes Project Consortium.","year":"2015","unstructured":"1000 Genomes Project Consortium. et al. A global reference for human genetic variation. Nature 526, 68\u201374 (2015).","journal-title":"Nature"},{"key":"168_CR31","doi-asserted-by":"publisher","first-page":"e64683","DOI":"10.1371\/journal.pone.0064683","volume":"8","author":"X Jia","year":"2013","unstructured":"Jia, X. et al. Imputing amino acid polymorphisms in human leukocyte antigens. PLoS ONE 8, e64683 (2013).","journal-title":"PLoS ONE"},{"key":"168_CR32","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1038\/ng1847","volume":"38","author":"AL Price","year":"2006","unstructured":"Price, A. L. et al. Principal components analysis corrects for stratification in genome-wide association studies. Nat. Genet. 38, 904\u2013909 (2006).","journal-title":"Nat. Genet."},{"key":"168_CR33","doi-asserted-by":"publisher","first-page":"2336","DOI":"10.1093\/bioinformatics\/btq419","volume":"26","author":"RJ Pruim","year":"2010","unstructured":"Pruim, R. J. et al. LocusZoom: regional visualization of genome-wide association scan results. Bioinformatics 26, 2336\u20132337 (2010).","journal-title":"Bioinformatics"},{"key":"168_CR34","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1038\/clpt.2008.89","volume":"84","author":"DM Roden","year":"2008","unstructured":"Roden, D. M. et al. Development of a large-scale de-identified DNA biobank to enable personalized medicine. Clin. Pharmacol. Ther. 84, 362\u2013369 (2008).","journal-title":"Clin. Pharmacol. Ther."},{"key":"168_CR35","doi-asserted-by":"publisher","first-page":"e334","DOI":"10.1136\/amiajnl-2013-001999","volume":"20","author":"MF Davis","year":"2013","unstructured":"Davis, M. F. et al. Automated extraction of clinical traits of multiple sclerosis in electronic medical records. J. Am. Med. Inform. Assoc. 20, e334\u2013e340 (2013).","journal-title":"J. Am. Med. Inform. Assoc."},{"key":"168_CR36","doi-asserted-by":"publisher","first-page":"2643","DOI":"10.1038\/nprot.2014.174","volume":"9","author":"Y Guo","year":"2014","unstructured":"Guo, Y. et al. Illumina human exome genotyping array clustering and quality control. Nat. Protoc. 9, 2643\u20132662 (2014).","journal-title":"Nat. Protoc."},{"key":"168_CR37","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1038\/nature10251","volume":"476","author":"International Multiple Sclerosis Genetics Consortium.","year":"2011","unstructured":"International Multiple Sclerosis Genetics Consortium. et al. Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis. Nature 476, 214\u2013219 (2011).","journal-title":"Nature"},{"key":"168_CR38","doi-asserted-by":"publisher","first-page":"2001","DOI":"10.1002\/hep.22895","volume":"49","author":"MI Lucena","year":"2009","unstructured":"Lucena, M. I. et al. Phenotypic characterization of idiosyncratic drug-induced liver injury: the influence of age and sex. Hepatology 49, 2001\u20132009 (2009).","journal-title":"Hepatology"},{"key":"168_CR39","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2105-12-77","volume":"12","author":"X Robin","year":"2011","unstructured":"Robin, X. et al. pROC: an open-source package for R and S+ to analyze and compare ROC curves. BMC Bioinforma. 12, 77 (2011).","journal-title":"BMC Bioinforma."},{"key":"168_CR40","doi-asserted-by":"publisher","first-page":"837","DOI":"10.2307\/2531595","volume":"44","author":"ER DeLong","year":"1988","unstructured":"DeLong, E. R., DeLong, D. M. & Clarke-Pearson, D. L. Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics 44, 837\u2013845 (1988).","journal-title":"Biometrics"}],"container-title":["Nature Genetics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/s41588-018-0168-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41588-018-0168-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41588-018-0168-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,20]],"date-time":"2023-05-20T18:19:47Z","timestamp":1684606787000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41588-018-0168-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,7,16]]},"references-count":40,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2018,8]]}},"alternative-id":["168"],"URL":"https:\/\/doi.org\/10.1038\/s41588-018-0168-y","relation":{},"ISSN":["1061-4036","1546-1718"],"issn-type":[{"value":"1061-4036","type":"print"},{"value":"1546-1718","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,7,16]]},"assertion":[{"value":"2 December 2016","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 May 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 July 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"K.K. has a consulting agreement with Emerald Lake Safety. E.M.Y. is an investigator of clinical trials sponsored by Gilead, Merck, Vertex, Hoffman LaRoche, Abbvie, Janssen, Boeringher Ingelheim, Intercept, and Genfit. He has also received honoraria for continuing medical education lectures from Merck Canada and Gilead Canada, spoken at Advisory Board Meetings of Boeringher Ingelheim Canada, Hoffman LaRoche Canada, Abbvie Canada, and Celgene Canada (for which he received an honorarium), and is a member of the Gilead Canada compassionate release program adjudication committee, for which he received an honorarium. A.T. has received grant support from Hoffman la Roche, Sanofi Genzyme, Chugai, Novartis, and Biogen, as well as performing consultancy work for Biogen, EMD Serono, Hoffman la Roche, Sanofi Genzyme, and Teva Neuroscience. R.A.M. has conducted clinical trials for Sanofi-Aventis, and receives research funding from the CIHR, National MS Society, MS Society of Canada, Research Manitoba, Consortium of MS Centers, Crohn\u2019s and Colitis Canada, and Waugh Family Chair in Multiple Sclerosis. In the past two years, M.K. or M.K.\u2019s institution (London Health Sciences Centre and Department of Neurological Sciences, Western University) has received research support or grants from CIHR. T.L.C. was a principal investigator for a research study for Biogen Idec Canada, has received honoraria for lectures from EMD Merck Serono Canada, Biogen Idec Canada, Teva Canada Innovation, and Genzyme, has participated in or spoken at Advisory Board Meetings of EMD Merck Serono, Teva Canada Innovation, Biogen Idec Canada, Genzyme, and Novartis (for which an honorarium and travel support were received in exchange for attendance). P.D. has received support as a consultant, membership on advisory councils, and grants from the pharmaceutical industry, and is funded by the MS Society of Canada and CIHR. N.C. has consulting agreements with Abbvie, Lilly, DS Biopharma (Afimmune), Tobira (Allergan), NuSirt, Celgene, Axovant, Shire, and Madrigal, and has received research grants from Cumberland, Galectin, and Intercept. M.W. and P.H. receive funding from the Swedish Research Council (Medicine 521-2011-2440 and 521-2014-3370) and Clinical Research Support (ALF) at Uppsala University. M.W. has also received grants from the Swedish Heart and Lung Foundation (20120557 and 20140291). Z.X. was a recipient of the Clinician Scientist Development Award from the National Multiple Sclerosis Society and American Academy of Neurology, and is supported by NINDS NIH K08-NS079493 and NINDS R01 NS098023. P.L.D.J. has received research funding from Sanofi\/Genzyme and Biogen, and has consulted for Teva Pharmaceuticals and Sanofi\/Genzyme. C.J.D.R. receives funding support from the CIHR, Canadian Foundation for Innovation, Canadian Hearing Foundation, BC Children\u2019s Hospital Foundation, Child & Family Research Institute, Canadian Gene Cure Foundation, Teva Pharmaceutical Industries, Genome BC, and CIHR Drug Safety and Effectiveness Network. H.T. is the Canada Research Chair for Neuroepidemiology and Multiple Sclerosis, and currently receives research support from the National MS Society, CIHR, MS Society of Canada, and MS Scientific Research Foundation. In the past five years, H.T. has received support from the Multiple Sclerosis Society of Canada (Don Paty Career Development Award), Michael Smith Foundation for Health Research (Scholar Award), and UK MS Trust. H.T. has received speaker honoraria and\/or travel expenses to attend conferences from the Consortium of MS Centres (2013), National MS Society (2014 and 2016), ECTRIMS (2013\u20132018), Biogen Idec (2014), and American Academy of Neurology (2013\u20132016). All speaker honoraria were either declined or donated to an MS charity or unrestricted grant for use by H.T.\u2019s research group. B.C.C. currently receives research funding from the CIHR, Genome Canada, Genome British Columbia, and British Columbia Children\u2019s Hospital Research Institute (Vancouver, Canada), and has previously received matching funds support for Genome Canada funding from Pfizer Canada (unrestricted).","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}